国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水

 
Guideview > FDA
  • Betta Pharmaceuticals: ALK Inhibitor Ensartinib Approved by FDA
    Betta Pharmaceuticals: ALK Inhibitor Ensartinib Approved by FDA FDA Betta Pharmaceuticals' Ensartinib (Ensacove), a next-generation ALK inhibitor, has been approved by the FDA for treating ALK-positive, advanced or metastatic NSCLC patients who haven't received prior ALK therapy, offering a new treatment option with promising results.
  • The Legendary Liver Disease Drug Descends from the Pedestal
    The Legendary Liver Disease Drug Descends from the Pedestal FDA Ocaliva (Obeticholic acid), a once-promising liver disease drug, faces setbacks in both the US and Europe. After failing to secure MASH approval and with declining sales, its future remains uncertain.
  • 2024 FDA Approved Small Molecule Drugs
    2024 FDA Approved Small Molecule Drugs FDA Discover the FDA-approved small molecule drugs of 2024, covering treatments for rare diseases, cancers, and chronic conditions. From innovative therapies like Iqirvo for primary biliary cholangitis to breakthrough options in neurology and oncology.
  • FDA Approved Summay - November 2024
    FDA Approved Summay - November 2024 FDA November 2024 FDA approvals include treatments for rare diseases, cancers, diabetes, and more. Highlights include Applied Therapeutics' Govorestat for galactosemia and UCB's Bimzelx for hidradenitis suppurativa. Explore key updates on new therapies.
  • FDA Accelerated Approval Market Withdrawal
    FDA Accelerated Approval Market Withdrawal FDA Explore the FDA’s accelerated approval pathway and its impact on the market, highlighting five drugs—Oxbryta, Aduhelm, Exkivity, Ukoniq, and Zydelig—that were withdrawn after initial approval. Understand the challenges and risks associated with accelerated drug approvals.
  • FDA Approved Summay - October 2024
    FDA Approved Summay - October 2024 FDA Explore the latest FDA drug approvals for October 2024, including treatments for Alzheimer's, cancer, Parkinson’s, and rare diseases, along with expanded indications for leukemia and pediatric care.
  • 100 Hospitalized, 10 Dead! Novo Nordisk Issues Warning
    100 Hospitalized, 10 Dead! Novo Nordisk Issues Warning Novo Nordisk Novo Nordisk warns after 100 hospitalizations and 10 deaths linked to generic versions of its weight loss and diabetes drugs, Wegovy and Ozempic. The company urges the FDA to ban unsafe generics due to complex formulations and safety concerns.
  • FDA Approval of Emrosi for Rosacea Treatment
    FDA Approval of Emrosi for Rosacea Treatment FDA FDA approves Journey Medical's Emrosi?, a 40 mg extended-release minocycline capsule, for treating adult rosacea. Supported by successful Phase III trials, Emrosi is set to launch in the U.S. by mid-2025 as a new oral standard for rosacea treatment.
  • Pfizer RSV Vaccine Approval
    Pfizer RSV Vaccine Approval Pfizer Pfizer's RSV vaccine, Abrysvo, has received FDA approval for use in high-risk adults aged 18-59, expanding its reach beyond older adults and pregnant women. This decision follows a successful Phase III trial, promising enhanced protection against respiratory syncytial virus (RSV) infections.
  • FDA Guidelines on Control of Nitrosamine Impurities
    FDA Guidelines on Control of Nitrosamine Impurities FDA Stay informed FDA's updated guidelines on controlling nitrosamine impurities in pharmaceuticals. In september 2024, these guidelines provide essential strategies for manufacturers to detect, prevent, and manage nitrosamine risks, ensuring safer drug production and compliance with health regulations.
< Pre 1...3456789...10Next >
枣强县| 临江市| 收藏| 黑龙江省| 抚松县| 连南| 达孜县| 渝北区| 曲阜市| 安达市| 瑞丽市| 双城市| 罗甸县| 涟水县| 达日县| 大丰市| 普定县| 当涂县| 和田县| 吉水县| 贺兰县| 巨野县| 新和县| 庐江县| 普安县| 满洲里市| 石棉县| 七台河市| 高州市| 高阳县| 南阳市| 周至县| 尚义县| 濮阳市| 得荣县| 赞皇县| 汪清县| 江阴市| 兴化市| 白城市| 讷河市|